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requiring dialysis in sub-Saharan Africa: a systematic review
Gloria Ashuntantang, Charlotte Osafo, Wasiu A Olowu, Fatiu Arogundade, Abdou Niang, John Porter, Saraladevi Naicker, Valerie A Luyckx
Summary
Background The burden of end-stage kidney disease (ESKD) in sub-Saharan Africa is unknown but is probably high. 
Access to dialysis for ESKD is limited by insufficient infrastructure and catastrophic out-of-pocket costs. Most patients 
remain undiagnosed, untreated, and die. We did a systematic literature review to assess outcomes of patients who 
reach dialysis and the quality of dialysis received.
Methods We searched PubMed, African Journals Online, WHO Global Health Library, and Web of Science for articles 
in English or French from sub-Saharan Africa reporting dialysis outcomes in patients with ESKD published between 
Jan 1, 1990, and Dec 22, 2015. No studies were excluded to best represent the current situation in sub-Saharan Africa.
Outcomes of interest included access to dialysis, mortality, duration of dialysis, and markers of dialysis quality in 
patients with ESKD. Data were analysed descriptively and reported using narrative synthesis.
Findings Studies were all of medium to low quality. We identified 4339 studies, 68 of which met inclusion criteria, 
comprising 24 456 adults and 809 children. In the pooled analysis, 390 (96%) of 406 adults and 133 (95%) of 140 children 
who could not access dialysis died or were presumed to have died. Among those dialysed, 2747 (88%) of 3122 adults 
in incident ESKD cohorts, 496 (16%) of 3197 adults in prevalent ESKD cohorts, and 107 (36%) of 294 children with 
ESKD died or were presumed to have died. 2508 (84%) of 2990 adults in incident ESKD cohorts discontinued dialysis 
compared with 64 (5%) of 1364 adults in prevalent ESKD cohorts. 41 (1%) of 4483 adults in incident ESKD cohorts, 
2280 (19%) of 12 125 adults in prevalent ESKD cohorts, and 71 (19%) of 381 children with ESKD received transplants. 
16 studies reported on management of anaemia, 17 on dialysis frequency, eight on dialysis accuracy, and 22 on 
vascular access for dialysis 
Interpretation Most patients with ESKD starting dialysis in sub-Saharan Africa discontinue treatment and die. Further 
work is needed to develop equitable and sustainable strategies to manage individuals with ESKD in sub-Saharan Africa.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
Chronic kidney disease (CKD) is an increasing, but still 
underappreciated, contributor to the global burden of 
disease.1 Best estimates from sub-Saharan Africa suggest 
12–23% of adults have CKD and are therefore at risk of 
developing end-stage kidney disease (ESKD).2–4 Since 
symptoms are largely non-specific and manifest late, 
diagnosis of CKD, especially at an early treatable stage, is 
easily missed.
Once the kidneys fail, renal replacement therapy by 
dialysis or transplantation is the only means of survival. 
Findings from studies in the past 5 years5,6 have suggested 
that between 2·3 million and 3·2 million people die 
yearly as a result of no access to dialysis. Estimation of the 
anticipated incidence of ESKD based on the prevalence of 
hypertension and diabetes suggests that only 1·5% of 
those requiring renal replacement therapy in sub-Saharan 
Africa receive it.5 Others reported a gap between those 
who require and receive dialysis of over 84% in sub-
Saharan Africa.6 There is no African renal registry, but 
reported dialysis incidence tends to be higher than 
prevalence in sub-Saharan Africa, suggesting high 
mortality among patients with ESKD.5–8 Where available, 
haemodialysis predominates because of frequent 
unavailability and higher costs of peritoneal dialysis and 
little availability of transplantation.9,10 In South Africa and 
Sudan, governments provide dialysis for ESKD. In 
South Africa, state-funded dialysis is accessed through a 
rationing process; in Sudan dialysis is offered to all, but at 
a reduced frequency (haemodialysis two instead of 
three times per week).11,12 In other sub-Saharan African 
countries, most expenses are paid out of pocket.12–15 
Therefore, in most of sub-Saharan Africa, patients with 
prevalent ESKD represent the elite few with enough 
resources to access long-term renal replacement therapy.
Dialysis outcomes are associated with the quality of 
dialysis delivered, which depends on the amount (ie, 
dose), duration, and frequency of dialysis; management 
of complications including anaemia; blood pressure; 
phosphate control; and laboratory monitoring. In 
haemodialysis, type of vascular access also affects 
morbidity and mortality.
We did a systematic review to explore outcomes and 
quality of dialysis in patients with incident and prevalent 
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ESKD in sub-Saharan Africa. Understanding the local 
realities of management of ESKD is important to 
highlight the daily clinical and moral dilemmas faced by 
clinicians, patients, and families when dialysis is paid for 
out of pocket, and to inform pragmatic policy 
development about ESKD care in resource-limited 
settings.
Methods
Search strategy and selection criteria
We registered our systematic literature review with 
PROSPERO (CRD42015015690) and completed it 
according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines.16 We searched 
PubMed, African Journals Online, the WHO Global 
Health Library, and Web of Science from Jan 1, 1990, to 
Dec 22, 2015, with relevant medical subject headings 
(appendix p 1). The search was restricted to publications 
in English and French. Additional references were 
identified through bibliography searches. Criteria for 
inclusion were all studies reporting outcomes related to 
access to dialysis, mortality, duration of dialysis, and 
markers of dialysis quality in patients with ESKD who 
needed or received dialysis in sub-Saharan Africa. 
Articles focusing exclusively on specific outcomes or 
subpop ulations, such as infections, and those reporting 
trans plantation outcomes were excluded, as were case 
reports (appendix p 1). Two authors (FA and VAL) 
screened titles and abstracts for eligibility. Articles 
meeting inclusion criteria and obtainable as full texts 
were reviewed in detail. Incident cohorts were defined as 
those reporting outcomes in patients with a new 
diagnosis of ESKD who needed, but either started or did 
not receive, dialysis. Prevalent ESKD cohorts were 
defined as those reporting outcomes in patients receiving 
long-term dialysis.
Quality assessment and data extraction
Study quality was assessed independently by two authors 
(VAL plus GA, CO, WAO, FA, or AN), as described 
previously (appendix pp 2–3).3,17 All articles meeting 
inclusion criteria were included in an attempt to 
minimise further bias and to reflect the current situation 
in sub-Saharan Africa, as reported previously.17 Individual 
study data were extracted into Microsoft Excel (Redmond, 
WA, USA; appendix p 4). 
Data analysis
In view of the variability in definitions of ESKD, length of 
follow-up, proportions of loss to follow-up, study sizes, 
and outcomes reported per study, data were analysed 
descriptively and reported using narrative synthesis.18,19 
Where possible, outcomes were reported within time-
frames for perspective; however, these data were not 
routinely available. Study populations were stratified by 
participant age (adult or paediatric) and by incident or 
prevalent cohorts. Outcomes were analysed separately 
for adults with incident and prevalent ESKD to test the 
hypothesis that outcomes are improved among patients 
with ESKD in sub-Saharan Africa who can achieve long-
term dialysis. Similarly, in view of more scarce resources 
and probably a lower ability to pay for ESKD care for 
children than adults in sub-Saharan Africa, outcomes in 
adult and paediatric populations were analysed separately. 
Data were reported as pooled estimates of outcome 
frequencies; however, in view of the variability between 
studies, the same outcomes are also reported in parallel 
as means (with SDs) of frequencies reported in individual 
studies, to show the breadth of interstudy variability 
of the various outcomes. Study denominators vary 
depending on the outcomes reported. Adults with 
incident and those with prevalent ESKD are reported 
separately; children were analysed overall because of the 
Research in context
Evidence before this study
Data on epidemiology and outcomes of end-stage kidney 
disease (ESKD) in sub-Saharan Africa are sparse. We did a 
systematic review of the literature to understand outcomes in 
patients with ESKD managed under existing circumstances in 
sub-Saharan Africa. We searched PubMed, African Journals 
Online, the WHO Global Health Library, and Web of Science 
between Jan 1, 1990, and Dec 22, 2015, with relevant medical 
subject headings. Additional references were found through 
screening of reference lists from identified articles. All retrieved 
and selected articles were published in English or French. No 
previous systematic reviews on this topic were identified.
Added value of this study
This study is, to our knowledge, the first to systematically 
analyse outcomes and quality of dialysis received in patients 
with ESKD in sub-Saharan Africa from several countries and 
centres. We found high mortality among patients with 
incident ESKD. Mortality was lower in patients with prevalent 
ESKD who had dialysis, which provides reason for optimism, 
but raises the important ethical question of how such dialysis 
could be sustainable on a broader scale in low-income 
countries with other health priorities and where opportunity 
costs (ie, the proportion of budget allocated to dialysis is not 
available for allocation to other health issues) are high. The 
quality of dialysis delivered is generally low, mostly because of 
economic factors.
Implications of all the available evidence
The increasing numbers of publications from sub-Saharan 
Africa in recent years is testament to the growing expertise in 
the region. As expertise grows, the health system must adapt; 
therefore, studies such as this are important initial steps to raise 
awareness of the clinical problem of ESKD as well as the large 
ongoing knowledge gaps among policy makers and the 
international community.
See Online for appendix
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small number of studies. Statistical analyses were not 
done because of the intrinsic differences between adults 
with incident versus prevalent ESKD and between 
adults and children, rendering comparisons artificial.
Role of the funding source
There was no funding source for this study. All authors 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
4339 records were found, of which 1151 were excluded; 
386 of 3188 screened studies underwent full review 
(figure 1), including one registry report from 
South Africa. No study was of high quality, mainly 
because participants were not representative of the 
larger ESKD population and because of missing data. 
68 studies (56 adult, 12 paediatric) from 15 countries 
satisfied inclusion criteria, 49 of which were published 
from 2010 onwards. 34 of the 68 studies met medium-
quality criteria. 26 adult and ten paediatric studies 
included patients with incident ESKD, 30 adult and 
two paediatric studies included patients with prevalent 
ESKD (appendix pp 5–11), and 37 adult and two paediatric 
studies included only patients who received dialysis. 
Ten studies provided details of missing data. 16 adult 
studies were prospective, seven cross-sectional, and 
33 retrospective. Two paediatric studies were prospective 
and ten retrospective. Study duration ranged from 
0·08 years to 19 years. All 12 paediatric and 26 of the 
adult studies were from academic hospitals; 24 adult 
studies were from city hospitals or haemodialysis units; 
three were from private dialysis units; and three reported 
whole-country data. 24 456 adults (10 354 with incident 
and 14 102 with prevalent ESKD) and 809 children 
(736 incident and 73 prevalent) were included in analyses 
(table 1).12,13
Mean patient ages ranged from 35·6 years (SD 13·2) to 
58·2 years (SD 15·0) in adult studies and from 9·8 years 
(range 3 months to 17 years) to 11·5 years (SD 3·0) in 
paediatric studies. Males predominated among adults 
and children (table 1). The term CKD was often used 
synonymously with ESKD. The definitions of CKD and 
ESKD used are reported in table 1. The causes of CKD 
Figure 1: Study selection
ESKD=end-stage kidney disease. *Includes African Index Medicus. †39 had receipt of dialysis as an inclusion criterion.
4339 records found
185 from African Journals Online
1187 from PubMed
1138 from Web of Science
1829 from WHO Global Health Library*
1151 duplicates or published before 1990
3188 titles and abstracts screened
2831 excluded
2797 did not meet eligibility criteria
34 manuscripts not obtainable as full text
318 excluded
44 specific causes of kidney disease 
1 conference abstract
9 donors 
11 data not relevant 
93 guidelines, reviews, editorials, or 
commentaries 
17 prevalence or incidence data
89 outcomes too specific (eg, peritonitis 
rates, tuberculosis in dialysis)
26 acute kidney injury alone
19 transplantation
9 reported same populations
29 records identified from other sources 
386 full-text articles screened
68 articles selected for systematic review†
12 paediatric ESKD studies
6 low quality
6 medium quality
2 studies of patients with prevalent 
ESKD
10 studies of patients with incident 
ESKD
30 studies of patients with prevalent 
ESKD
26 studies of patients with incident 
ESKD
56 adult ESKD studies
28 low quality
28 medium quality
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and ESKD were reported in 40 adult and 12 paediatric 
studies (appendix p 12).
The proportion of patients with incident ESKD who 
were able to access dialysis is outlined in table 2. Pooled 
analysis showed that 4221 of 8253 adults (51%; 15 studies) 
and 211 of 347 children (61%; eight studies) received at 
least one dialysis session. The mean percent access to 
dialysis across individual studies was 39·1% (SD 25·7) in 
adults and 47·4% (30·6) in children. Of 3692 adults with 
incident ESKD, 2980 (81%) received haemodialysis and 
712 (19%) received peritoneal dialysis (16 studies); these 
numbers were 11 186 (84%) and and 2194 (16%) among 
13 380 adults with prevalent ESKD (26 studies), and 
128 (46%) and 149 (54%) among 277 children (ten studies). 
Dialysis duration was reported in 35 adult and 
eight paediatric studies (table 2). Among those who 
started dialysis, 2572 of 4354 adults (59%; 23 studies) and 
94 of 192 children (49%; six studies) discontinued dialysis. 
In adults, 2508 of 2990 (84%; 13 studies) incident and 
64 of 1364 (5%; ten studies) prevalent patients 
discontinued dialysis after a mean of 6·5 (SD 5·3) 
sessions. The pooled proportion of children discontinuing 
dialysis was 94 of 192 (49%; six studies), and the mean 
percentage was 76·2% (SD 33·6). The proportions of 
adults and children continuing dialysis for at least 
3 months and at least 12 months are shown in table 2. 
The pooled proportion of adults with prevalent ESKD 
remaining on dialysis for at least 3 months was 3029 of 
3575 (85%; ten studies) and the mean of individual study 
frequencies was 63·4% (SD 24·0), compared with a 
pooled proportion of 295 of 3104 (10%; 16 studies) and 
mean of individual study frequencies of 14·1% (SD 12·6) 
in adults with incident ESKD. The durations of dialysis 
received in individual studies are shown in the appendix 
(pp 5–11). Compared with the full cohort, when studies 
from South Africa and Sudan were excluded, the 
proportions of people who discontinued dialysis were 
higher among both adults and children (78% and 86%, 
respectively; appendix p 13).
In the pooled analyses, overall known study mortality 
was higher in adults (3446 [32%] of 10 874; 35 studies) 
than in children (159 [24%] of 656; ten studies) and in 
incident (2966 [39%] of 7677; 17 studies) than in prevalent 
(480 [15%] of 3197; 18 studies) adult cohorts. However, 
overall study mortality might not represent ESKD 
mortality, because some studies included patients with 
CKD who did not require dialysis, and most did not 
account for patients lost to follow-up or leaving hospital 
against medical advice. 27 of 143 children (19%; 
three studies) had left hospital against medical advice, 
whereas 557 of 3087 adults (18%; 12 studies) and 188 of 
675 children (28%; eight studies) were lost to follow-up 
(table 3). We presumed that these patients probably died 
without further treatment. Including these patients and 
those who discontinued dialysis in the pooled analysis, 
known and presumed mortality occurred in 5128 of 
9057 adults (57%; 39 studies) and 266 of 426 children 
(62% 11 studies). Mortality was higher among adults with 
incident (4632 [79%] of 5860; 21 studies) than among 
those with prevalent ESKD (496 [16%] of 3197; 18 studies). 
Adult studies Paediatric studies 
(n=12)
Overall (n=56) Incident ESKD (n=26) Prevalent ESKD (n=30)
Number of countries 14 8 12 4
Patient inclusion period 1976–2014 1976–2013 1987–2014 1995–2013
Total number of patients with CKD or ESKD 24 456 10 354 14 102 809
In South Africa and Sudan only 15 063 2586 12 477 398
Excluding South Africa and Sudan 9393 7768 1625 411
Study duration (years)* 4·0 (4·5) 5·8 (5·1) 2·1 (2·3) 6·1 (2·8)
Sex†
Male 13 655/22 152 (62%) 5682/9401 (60%) 7973/12 751 (63%) 439/748 (59%)
Female 8497/22 152 (38%) 3719/9401 (40%) 4778/12 751 (37%) 309/748 (41%)
Male:female ratio, individual studies† 1·98 (1·09) 1·72 (0·78) 2·20 (1·39) 1·46 (0·34)
Definitions of CKD or ESKD used
Clinical 7 7 0 2
Laboratory (creatinine thresholds) 9 9 0 6
ESKD, glomerular filtration rate <15 mL/min 7 7 0 0
KDIGO or KDOQI 4 4 0 3
Dialysis requirement 41 11 30 2
Not mentioned 1 1 0 3
Data are mean (SD) or n/N (%), unless otherwise specified. CKD=chronic kidney disease. ESKD=end-stage kidney disease. KDIGO=Kidney Disease Improving Global Outcomes. 
KDOQI=Kidney Disease Outcomes Quality Initiative. *Data missing for four studies in adults with prevalent ESKD and one paediatric study. †Data missing for ten studies in 
adults (five incident ESKD and five prevalent ESKD) and four in children. 
Table 1: Study populations
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Leading causes of death were uraemia, volume overload 
(ie, too much water in their bodies that they could not 
excrete because of kidney failure), hypertension, 
discontinuation of dialysis, no vascular access, heart 
failure, stroke, or infections.20–26 
Overall pooled mortality among patients with ESKD 
who received dialysis was similar among adults 
(1302 [31%] of 4228; 25 studies) and children (90 [32%] of 
284; ten studies), but was higher among adults with 
incident ESKD (822 [80%] of 1031; seven studies) 
compared with prevalent ESKD (480 [15%] of 3197; 
18 studies; table 3). Among patients who needed but did 
not receive dialysis, pooled known and presumed 
mortality was similar in adults (390 [96%] of 406; 
three studies) and children (133 [95%] of 140; 
nine studies). Among adults with incident ESKD, the 
difference in known and presumed mortality between 
those who did and did not receive dialysis was small 
(2747 [88%] of 3122, 14 studies vs 390 [96%] of 406; 
three studies). When South Africa and Sudan were 
excluded from the analyses, pooled mortality among 
adults and children who received dialysis increased 
further (appendix p 14). Pooled known and presumed 
mortality was similar between adult patients with 
prevalent ESKD who received peritoneal dialysis 
(121 [19%] of 650; seven studies) or haemodialysis 
(301 [16%] of 1884; nine studies; appendix p 15).
15 adult studies reported use of intravenous iron or 
erythropoietin for renal anaemia (appendix p 16). Access 
to both drugs was scarce, leaving patients mainly reliant 
on blood transfusions (mean 61·5% [SD 15·2]; 
six studies). Use of any intravenous iron (1870 [65%] of 
2898; three studies vs 30 [25%] of 120; one study) or 
erythropoietin (2425 [74%] of 3287; nine studies vs 
65 [19%] of 348; three studies) was higher in prevalent 
versus incident cohorts. Means of individual study 
proportions were generally lower than pooled proportions. 
One paediatric study reported use of erythropoietin for 
less than 1 week in two of 24 children and blood 
transfusion in five of 25 children.27 Use of phosphate 
binders was reported in two of 42 and 19 of 45 patients in 
two adult studies.28,29 Haemodialysis vascular access was 
described in 22 adult studies. Overall, the mean 
proportion of patients with arteriovenous fistula was 
15·6% [SD 9·7] at the start of dialysis, but rose among 
prevalent patients over time (from 16·5% [10·9] to 
61·3% [26·2]; appendix p 16). No study described regular 
laboratory monitoring. Four studies reported use of 
four 2 L exchanges daily for continuous ambulatory 
peritoneal dialysis (usual dose), and one study described 
use of a peritoneal dialysis cycler.30–33 Frequency of 
haemodialysis was described in 17 studies (figure 2).12,24,26,34–47 
Most patients with prevalent ESKD received two 4 h 
sessions per week, but some received dialysis 
Adult studies Paediatric studies
Overall Incident Prevalent
Access to dialysis
Pooled 4221/8253 (51%; 15) 4221/8253 (51%; 15) NA 211/347 (61%; 8)
Individual studies 39·1% (25·7; 16) 39·1% (25·7; 16) NA 47·4% (30·6; 8)
Not dialysed although indicated
Pooled 3277/6797 (48%; 11) 3277/6797 (48%; 11) NA 106/323 (33%; 7)
Individual studies 56·6% (19·5; 11) 56·6% (19·5; 11) NA 41·6% (21·4; 7)
Known to stop dialysis although needed
Pooled 2572/4354 (59%; 23) 2508/2990 (84%; 13) 64/1364 (5%; 10) 94/192 (49%; 6)
Individual studies 51·4% (41·4; 23) 79·7% (27·5; 13) 14·7% (23·0; 10) 76·2% (33·6; 6)
Continued dialysis ≥3 months*
Pooled 3324/6589 (50%; 26) 295/3014 (10%; 16) 3029/3575 (85%; 10) 66/190 (35%; 7)
Individual studies 33·1% (32·9; 26) 14·1% (21·6; 16) 63·4% (24·0; 10) 29·6% (38·2; 7)
Continued dialysis ≥12 months†
Pooled 1598/3560 (45%; 13) 19/1472 (1%; 6) 1579/2088 (76%; 7) 3/6 (50%; 1)
Individual studies 36·4% (38·3; 13) 1·5% (2·3; 6) 66·3% (25·8; 7) No data
Recovery of enough renal function to come off dialysis
Pooled 34/1765 (2%; 9) 5/64 (8%; 3) 29/1701 (2%; 6) 2/20 (10%; 3)
Individual studies 4·9% (7·1; 9) 7·3% (12·6; 3) 3·7% (3·4; 6) 22·2% (38·5; 3)
Transplant received
Pooled 2321/16 608 (14%; 24) 41/4483 (1%; 11) 2280/12 125 (19%; 13) 71/381 (19%; 9)
Individual studies 6·3% (8·4; 24) 1·7% (1·3; 11) 10·3% (9·9; 13) 19·0% (26·6; 9)
Data are n/N (%; number of studies) or mean (SD; number of studies). NA=not applicable. *Countries reporting dialysis duration ≥3 months: Burkina Faso, Cameroon, 
Democratic Republic of the Congo, Ethiopia, Ghana, Malawi, Nigeria, Senegal, South Africa, and Sudan. †Countries reporting dialysis duration ≥12 months: Cameroon, 
Ethiopia, Ghana, Nigeria, Senegal, South Africa, Sudan. 
Table 2: Renal replacement therapy for end-stage kidney disease
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intermittently as resources permitted. Eight adult studies 
reported monitoring of dialysis adequacy, which was 
infrequent and often suboptimum (appendix p 17). The 
delivered dialysis dose tended to be higher among those 
receiving peritoneal dialysis than haemodialysis.
Nine adult and three paediatric studies described 
recovery of enough renal function for patients to 
discontinue dialysis. In pooled analyses, five of 64 adults 
with incident ESKD (8%; three studies) and two of 
20 children (10%; three studies) came off dialysis 
(table 2). 2321 of 16 608 adults (14%; 24 studies) and 71 of 
381 children (19%; nine studies) received a kidney 
transplant. A transplant was received by more adults 
with prevalent than with incident ESKD (2280 [19%] of 
12 125 vs 41 [1%] of 4483). Transplantations were often 
done outside the country (data not shown). When studies 
from South Africa and Sudan were excluded, the 
proportion of patients receiving a transplant decreased 
substantially, to 54 (1%) of 4808 adults and four (3%) of 
158 children (appendix p 13).
Discussion
The public health impact of ESKD does not lie exclusively 
in the numbers of patients affected, but also in the 
diagnostic and therapeutic challenges of management, 
which impose a substantial burden on individuals and the 
health system in resource-limited settings. So far, mostly 
single-centre studies have highlighted the local challenges 
in management of ESKD in sub-Saharan Africa. In this 
systematic review, we show that, even among the few 
people who reach a diagnosis of ESKD in sub-Saharan 
Africa, presumed and known mortality among adults and 
children was high, and was over 95% when patients were 
unable to access dialysis. Among patients who did start 
dialysis, mortality remained high, largely because of late 
presentation, frequent dialysis discontinuation, and 
suboptimum dialysis quality. Overall, only around 10% of 
adults with incident ESKD and 35% of children remained 
on dialysis for at least 3 months. Worldwide, higher 
mortality is noted within the first 120 days of starting 
dialysis compared with later months, which is largely 
attributed to comorbid illness, patient age, withdrawal 
from dialysis, or poor care before dialysis.48 Although 
some of these criteria might explain the differences in 
mortality between patients with incident versus prevalent 
ESKD in sub-Saharan Africa, the attrition described in 
most studies was a result of the inability to pay for dialysis, 
occurring usually within the first 2 weeks of initiation 
(mean cost US$100–150 per haemodialysis session).24,49 
The adult ESKD population in sub-Saharan Africa tends 
to be young with few comorbidities; therefore, when 
patients do manage to pay for long-term dialysis, even 
though dialysis quality might be suboptimal, outcomes 
are much improved, with over 75% of patients with 
prevalent ESKD remaining on dialysis for over 1 year. 
Outcomes in children were generally between those noted 
Adult studies Paediatric studies
Overall Incident Prevalent
Known and presumed mortality*
Pooled 5128/9057 (57%; 39) 4632/5860 (79%; 21) 496/3197 (16%; 18) 266/426 (62%; 11)
Individual studies 53·0% (34·0; 39) 79·6% (19·0; 21) 21·9% (15·9; 18) 70·4% (29·8; 11)
Mortality without dialysis although indicated
Known†
Pooled NA 185/212 (87%; 2) NA 43/51 (84%; 4)
Individual studies NA 80·1% (13·1; 2) NA 81·7% (15·8; 4)
Known and presumed*
Pooled NA 390/406 (96%; 3) NA 133/140 (95%; 9)
Individual studies NA 95·6% (7·6; 3) NA 96·2% (8·0; 9)
Mortality with dialysis
Known†
Pooled 1302/4228 (31%; 25) 822/1031 (80%; 7) 480/3197 (15%; 18) 90/284 (32%; 10)
Individual studies 32·1% (27·1; 25) 60·0% (31·0; 7) 21·2% (15·7; 18) 50·5% (32·2; 10)
Known and presumed*
Pooled 3243/6319 (51%; 32) 2747/3122 (88%; 14) 496/3197 (16%; 18) 107/294 (36%; 10)
Individual studies 48·7% (35·3; 32) 83·0% (19·4; 14) 21·9% (15·9; 18) 57·3% (35·1; 10)
Left hospital against medical advice, 
pooled
ND ND ND 27/143 (19%; 3)
Lost to follow-up, pooled 557/3087 (18%; 12) 443/1633 (27%; 7) 114/1454 (8%; 5) 188/675 (28%; 8)
Data are n/N (%; number of studies) or mean (SD; number of studies). NA=not applicable. ND=no data. *Patients with end-stage kidney disease who were known to have 
died plus those who left hospital against medical advice, were lost to follow-up, or stopped dialysis although indicated and therefore are presumed to have died without 
further treatment. †Patients known to have died. 
Table 3: Mortality in children and adults with end-stage kidney disease
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for adults with incident and prevalent ESKD; however, a 
high proportion of children left hospital against medical 
advice, suggesting that families make affordability 
decisions soon after diagnosis and there is little long-term 
dialysis available for children outside of South Africa and 
Sudan. Prospective studies are needed to identify 
differences in causes of death, reasons for dialysis 
discontinuation, and factors associated with dialysis 
continuation among patients with incident and prevalent 
ESKD and in children with ESKD in sub-Saharan Africa, 
to inform clinical decision making and policy development 
around ESKD care.
This systematic review complements our recent review 
on the outcomes of patients with acute kidney injury in 
sub-Saharan Africa, where access to dialysis and survival 
were also low.17 The numbers of patients with acute 
kidney injury and ESKD who remain undiagnosed are 
unknown. Both reviews show that, even among patients 
who have resources to reach a diagnosis of kidney failure, 
dialysis is largely out of reach. Much attention has been 
focused recently on the diagnosis and management 
(including dialysis) of acute kidney injury because this 
disorder is less costly than ESKD.50 Although this strategy 
might be efficient, this narrow focus raises equity 
questions for patients with other kidney diseases. 
Awareness must be raised about the plight of all patients 
with kidney failure in sub-Saharan Africa.
Recent publications have estimated the large unmet 
need for dialysis and a systematic review addressed the 
scarcity of trained staff in sub-Saharan Africa.5,6,51–55 
Where dialysis is available, even where partial 
government subsidies exist, many patients stop 
treatment and die once their resources are depleted 
because vascular access, laboratory and radiological 
testing, drug treatment, or transportation are not 
covered.33,38,41,56,57 Such high attrition rates raise ethical 
questions about offering patients dialysis when their 
resources are known to be inadequate to sustain 
treatment. However, some patients, being fully informed, 
still wish to try. In countries where full dialysis costs are 
covered by the government, although individual 
outcomes are improved, access is still limited by official 
rationing (South Africa), out-of-pocket costs needed for 
transportation and drugs (Sudan), and insufficient 
dialysis infrastructure to treat all those in need.11,12,22,31
The quality of dialysis delivered is also resource-
dependent, and many patients cannot afford, or dialysis 
centres cannot provide, regular dialysis. Dialysis quality, 
as measured by use of erythropoiesis-stimulating drugs; 
permanent vascular access; dialysis dose; dialysis 
adequacy; and access to transplantation, was poor even 
among those able to afford long-term dialysis. One 
study35 described repeated femoral vein catheterisation as 
the predominant form of dialysis access in 105 of 
Figure 2: Proportion of dialysis sessions received per week in incident and prevalent haemodialysis populations by country
The standard haemodialysis dose is three sessions of 4 h per week, but varied in some studies. Each column represents data from one study or country; studies from 
the same country are shown separately when the dialysis frequencies differed. *Ranged from one dialysis session only to one session every 2 weeks to 2 months. 
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120 patients because of cost. Measurement of dialysis 
adequacy was rarely reported. However, when measured 
in Sudan, a proportion of patients achieved target 
adequacy despite the lower haemodialysis dose, and 
dialysis quality might be better with peritoneal dialysis 
under the circumstances.12,45 This finding should provide 
a rationale to advocate more affordable peritoneal dialysis 
for ESKD.10,33,58
Common barriers contributing to mortality in ESKD in 
sub-Saharan Africa are shown in figure 3. The most 
common patient barriers to accessing dialysis and 
achieving adequate dialysis quality are the unaffordable 
costs of dialysis, transportation, drug treatment, vascular 
access, and transplantation workup.12,29,35,49 In view of the 
unexpected low prevalence of HIV as a cause of ESKD, 
some underlying diseases and comorbid conditions might 
also represent barriers.11,49,59 Female sex is a systematic 
barrier to access to ESKD care in sub-Saharan Africa.60 In 
the reviewed studies, young children were under-
represented, potentially because of unwillingness to pay 
and paucity of facilities for infants.61 Infrastructural 
barriers include the scarcity of dialysis facilities, which 
when available are predominantly in urban centres, might 
be dependent on donated outdated equipment that cannot 
be maintained, are often affected by staff and stock 
shortages, and cannot meet the clinical need.33,38,62,63 
Identification of common barriers occurring in daily 
practice is important to stimulate debate about pragmatic 
approaches to prevention, diagnosis, and management of 
ESKD in sub-Saharan Africa.
This systematic review has important limitations and 
several strengths. In view of the scarcity of high-quality 
studies, all papers were included in an attempt to reduce 
further bias by exclusion. The diagnosis of ESKD was not 
uniform across studies and in view of the clinical 
circumstances in much of sub-Saharan Africa, the 
distinction between acute kidney injury and ESKD was 
not always possible. Therefore, some patients with acute 
kidney injury might have been incorrectly diagnosed as 
having ESKD. Erroneous inclusion of patients with acute 
kidney injury could have biased the outcomes towards 
underestimation of mortality in ESKD, especially among 
adults with incident ESKD. Not all studies reported on all 
outcomes; therefore, denominators vary for each 
analysis, but the data presented represent the best 
available and patient numbers are high, which are 
important strengths. The finding that about 40–50% of 
patients in the identified studies received dialysis at least 
once is probably a substantial overestimate of the true 
figure, as reported in 2015.6 Almost all studies were from 
centres with dialysis facilities and therefore represent 
only patients who received a diagnosis of ESKD and had 
reached a dialysis unit. Thus, publication bias exists in 
terms of access to dialysis, but outcomes reported remain 
relevant. The outcomes and dialysis quality measures are 
poor and represent the daily reality of dialysis practice in 
many countries in sub-Saharan Africa. Dialysis duration 
and mortality rates were reported with varying follow-up 
times in individual studies. However, we believe that the 
small proportions of patients remaining on long-term 
dialysis is probably a valid indirect indicator of dialysis 
duration and high early mortality in patients with ESKD. 
Differences between pooled proportions and means of 
individual study frequencies for some outcomes show 
variability between studies. These differences are likely 
to reflect differences in study size, but also probably 
reflect many other factors such as local logistics, 
infrastructure, skill, geographical location, and 
distribution of poverty or affluence of patients included, 
Figure 3: Barriers to care in end-stage kidney disease
Flow diagram showing barriers in access to dialysis contributing to mortality in ESKD in many 
sub-Saharan African countries. Green arrows show factors present to facilitate diagnosis of ESKD or referral for or 
access to dialysis; red arrows show absence of these factors. Most barriers are related to access to care, access to 
diagnosis, out-of-pocket payments needed, and infrastructural resources. ESKD=end-stage kidney disease. Figure 
adapted from Olowu and colleagues.17
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which will have affected study outcomes. The overall 
heterogeneity of the data emphasises the urgent need for 
good systematic data collection on incidence and 
prevalence of ESKD as well as the need to perform and 
publish higher quality studies in the region. Despite the 
data only representing 15 countries in sub-Saharan 
Africa, the consistency of problems encountered and 
poor patient outcomes across studies suggest 
generalisability of these findings. Despite the inherent 
limitations, this systematic review provides important 
insights to encourage and inform policy development 
and health-system-wide planning to address ESKD in 
sub-Saharan Africa.
Dialysis facilities and dialysis populations are 
expanding in sub-Saharan Africa.15 The consequences for 
the individual, in terms of catastrophic expenditure and 
life or death, and for the health system, in terms of 
opportunity costs and equity, cannot be ignored. Few 
countries in sub-Saharan Africa have official policies for 
renal replacement therapy, and some governments are 
reluctant to broach the debate about coverage of renal 
replacement therapy, which is fraught with ethical 
dilemmas. Without formalised criteria or official 
guidelines, access to dialysis is haphazard, often 
depending on luck if facilities are available, and ability to 
pay. The burden of so-called choice between life and 
death is shifted to individual clinicians, patients, and 
families, imposing substantial moral distress.64 However, 
before development of ESKD policies, existing knowledge 
gaps about the local burden of disease, outcomes, 
assessment of current treatment capacity, and the 
socioeconomic implications of kidney disease must be 
filled.65 Engaging in public debate about the justice 
implications of starting expensive programmes such as 
dialysis, which deliver acceptable quality care, in 
environments where opportunity costs are likely to be 
very high is important to develop sustainable and 
equitable solutions for patients with kidney disease.
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